Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

Introduction: Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In this exploratory analysis, outcomes were evaluated...

Full description

Bibliographic Details
Main Authors: Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park, Jean-Frederic Blanc, Ho Yeong Lim, Albert Tran, Yi-Wah Chan, Paul McAdam, Evelyn Wang, Ann-Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou-Alfa
Format: Article
Language:English
Published: Karger Publishers 2021-12-01
Series:Liver Cancer
Subjects:
hepatocellular carcinoma
plasma biomarkers
prognostic factors
cabozantinib
Online Access:https://www.karger.com/Article/FullText/519867

Internet

https://www.karger.com/Article/FullText/519867

Similar Items